Abstract

In the early stage of drug developing process, pharmaceutical companies are interested in whether the candidate compounds show interactions with other drugs. Since most of the drugs are metabolized in human liver, these early stage pharmacokinetic experiments are conducted at different levels of concentrations of the compound under study with randomly selected liver tissues. As enzymes play a vital role in metabolizing drugs, examination of association between compound and different enzymes could be useful in understanding the compound’s potentiality of adverse drug reactions. Michaelis-Menten model is often used to examine the association between enzymes and compound. In many cases transform-both-sides Michales-Menten model fits pharmacokinetic data well compared to the regular Michaelis-Menten model. In this talk, we will discuss optimum designs for such transform-both-sides Michaelis-Menten model when information on covariates associated with randomly selected liver tissues are available.